WO2005115410A2 - Inhibiteurs de cytidine-desaminases dependants du contexte et utilisations correspondantes - Google Patents

Inhibiteurs de cytidine-desaminases dependants du contexte et utilisations correspondantes Download PDF

Info

Publication number
WO2005115410A2
WO2005115410A2 PCT/US2005/016001 US2005016001W WO2005115410A2 WO 2005115410 A2 WO2005115410 A2 WO 2005115410A2 US 2005016001 W US2005016001 W US 2005016001W WO 2005115410 A2 WO2005115410 A2 WO 2005115410A2
Authority
WO
WIPO (PCT)
Prior art keywords
cytidine deaminase
context
deaminase inhibitor
dependent
nucleoside
Prior art date
Application number
PCT/US2005/016001
Other languages
English (en)
Other versions
WO2005115410A3 (fr
Inventor
Joseph E. Wedekind
Harold C. Smith
Original Assignee
University Of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Rochester filed Critical University Of Rochester
Priority to US11/579,660 priority Critical patent/US8158770B2/en
Publication of WO2005115410A2 publication Critical patent/WO2005115410A2/fr
Publication of WO2005115410A3 publication Critical patent/WO2005115410A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Cette invention porte sur des inhibiteurs de la cytidine-désaminase (inhibiteurs de la Cytidine-désaminase) de cytidine-désaminases ainsi que sur leurs utilisations.
PCT/US2005/016001 2004-05-06 2005-05-06 Inhibiteurs de cytidine-desaminases dependants du contexte et utilisations correspondantes WO2005115410A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/579,660 US8158770B2 (en) 2004-05-06 2005-05-06 Content dependent inhibitors of cytidine deaminases and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56849004P 2004-05-06 2004-05-06
US60/568,490 2004-05-06

Publications (2)

Publication Number Publication Date
WO2005115410A2 true WO2005115410A2 (fr) 2005-12-08
WO2005115410A3 WO2005115410A3 (fr) 2008-06-26

Family

ID=35451393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/016001 WO2005115410A2 (fr) 2004-05-06 2005-05-06 Inhibiteurs de cytidine-desaminases dependants du contexte et utilisations correspondantes

Country Status (2)

Country Link
US (1) US8158770B2 (fr)
WO (1) WO2005115410A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500713A (ja) * 2007-10-16 2011-01-06 エイザイ インコーポレイテッド シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン
US8158605B2 (en) 2007-09-26 2012-04-17 Mount Sinai School Of Medicine Azacytidine analogues and uses thereof
US8324180B2 (en) 2009-04-06 2012-12-04 Eisai Inc. Compositions and methods for treating cancer
US8329665B2 (en) 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
US8329666B2 (en) 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
US8349792B2 (en) 2006-12-19 2013-01-08 Cyclacel Limited Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
US11981703B2 (en) 2017-08-17 2024-05-14 Sirius Therapeutics, Inc. Polynucleotide constructs

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2869852A4 (fr) * 2012-07-09 2016-04-20 Metheor Therapeutics Corp Inhibiteurs oligonucléotidiques d'adn méthyltransférases et leur utilisation dans le traitement de maladies
WO2015106272A1 (fr) * 2014-01-13 2015-07-16 Harki Daniel A Inhbiteurs de petites molécules d'apobec3g et d'apobec3b
MX2018006790A (es) 2015-12-03 2019-05-02 Epidestiny Inc Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos.
EP3641783A4 (fr) * 2017-06-22 2021-03-10 University Of Virginia Patent Foundation Médecine atomique activée par protons
CN108265095B (zh) * 2017-12-13 2020-11-24 东莞理工学院 一种15n稳定性同位素标记5-甲基脱氧胞苷的制备方法
US20240140983A1 (en) * 2021-01-26 2024-05-02 Massey University Single stranded dna enzyme inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH502546A (de) 1968-01-31 1971-01-31 Reich Arturo Kennzeichenträger, insbesondere für Schlauchleitungen
SE505219C2 (sv) 1992-04-29 1997-07-14 Partex Marking Systems Ab Märke för identifiering av elektriska ledningar
WO1995005851A1 (fr) 1993-08-20 1995-03-02 St. Luke's-Roosevelt Hospital Center Compositions relatives au facteur viral infectieux de hiv, utilisations prophylactiques et therapeutiques
US5468022A (en) 1994-06-14 1995-11-21 Massachusetts Institute Of Technology Sample tube identification flag
US6041253A (en) 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
DE19535144A1 (de) 1995-09-21 1997-03-27 Bosch Siemens Hausgeraete Kältegerät
US5866333A (en) 1996-03-01 1999-02-02 Regents Of The University Of California Screening methods to detect mRNA targets of editing enzymes
US5747319A (en) 1996-07-25 1998-05-05 Incyte Pharmaceuticals, Inc. Human mRNA editing enzyme
AU739469B2 (en) 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US5804185A (en) 1997-03-13 1998-09-08 Incyte Pharmaceuticals, Inc. RNA editing enzyme REE-2
FR2773079B1 (fr) 1997-12-30 2002-05-17 Itzik Harosh Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
US20040115184A1 (en) 2001-02-27 2004-06-17 Smith Harold C Methods and compositions for modifying apolipoprotein b mrna editing
DE60215626T2 (de) 2001-04-06 2007-08-30 Thomas Jefferson University Antagonist für die multimerisierung von hiv-1 vif-protein
CA2495478A1 (fr) 2002-08-05 2004-02-12 University Of Rochester Proteines chimeres a domaine de transduction proteique/domaine desaminase, composes associes et utilisations correspondantes
ATE388961T1 (de) 2003-05-23 2008-03-15 Univ Oregon Health & Science Verfahren zur identifikation von inhibitoren
WO2005023985A2 (fr) 2003-09-03 2005-03-17 University Of Rochester Activateurs de cytidine-desaminase, activateurs de desoxycytidine-desaminase, antagonistes du vif et procedes de criblage des molecules correspondantes
WO2005047476A2 (fr) 2003-11-10 2005-05-26 Rigel Pharmaceuticals, Inc. Inhibition de la replication retrovirale par modulation de l'ubiquitylation de cellules hotes
FR2870855A1 (fr) 2004-05-27 2005-12-02 Obe Therapy Biotechnology Soc Procede de criblage a haut debit pour l'identification de molecules inhibitrices de l'activite d'enzymes d'edition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ASHLEY ET AL.: 'Inhibition of Escherichia coli cytidine deaminase by a phosphapyrimidine nucleoside' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 259, 1984, pages 13621 - 13627 *
CARLOW ET AL.: 'Role of glutamate-104 in generating a transition state analogue inhibitor at the active site of cytidine deaminase' BIOCHEMISTRY vol. 35, 1996, pages 948 - 954 *
JEONG ET AL.: 'Carbocyclic analogues of the potent cytidine deaminase inhibitor 1-(b-D-ribofuranosyl)-1,2-dihydropyrimidin- 2-one (Zebularine)' J. MED. CHEM. vol. 41, 1998, pages 2572 - 2578 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349792B2 (en) 2006-12-19 2013-01-08 Cyclacel Limited Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent
US8158605B2 (en) 2007-09-26 2012-04-17 Mount Sinai School Of Medicine Azacytidine analogues and uses thereof
US8399420B2 (en) 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof
US8618075B2 (en) 2007-10-16 2013-12-31 Eisai Inc. Certain compounds, compositions and methods
US8268800B2 (en) 2007-10-16 2012-09-18 Eisai Inc. Certain compounds, compositions and methods
JP2011500713A (ja) * 2007-10-16 2011-01-06 エイザイ インコーポレイテッド シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン
US8951987B2 (en) 2007-10-16 2015-02-10 Otsuka Pharmaceuticals Co., Ltd. Certain compounds, compositions and methods
US9567363B2 (en) 2007-10-16 2017-02-14 Otsuka Pharmaceutical Co., Ltd. Certain compounds, compositions and methods
US8329665B2 (en) 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
US8329666B2 (en) 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
US8324180B2 (en) 2009-04-06 2012-12-04 Eisai Inc. Compositions and methods for treating cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
US9040501B2 (en) 2009-04-06 2015-05-26 Otsuka Pharmaceutical Co., Ltd. Compositions and methods for treating cancer
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
US11981703B2 (en) 2017-08-17 2024-05-14 Sirius Therapeutics, Inc. Polynucleotide constructs

Also Published As

Publication number Publication date
WO2005115410A3 (fr) 2008-06-26
US20090099105A1 (en) 2009-04-16
US8158770B2 (en) 2012-04-17

Similar Documents

Publication Publication Date Title
US8158770B2 (en) Content dependent inhibitors of cytidine deaminases and uses thereof
JP7148936B2 (ja) ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物
AU2018352221B2 (en) Peptides and nanoparticles for intracellular delivery of mRNA
AU2017213503B2 (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP7347830B2 (ja) Ｒｎａ編集のための人工核酸
US20180230464A1 (en) Chemically Ligated RNAs for CRISPR/Cas9-lgRNA Complexes as Antiviral Therapeutic Agents
Wagner et al. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides
TWI723363B (zh) 用於治療癌症之包含引導rna及內切酶的藥學組成物
Mehdipour et al. The role of DNA-demethylating agents in cancer therapy
US20040191905A1 (en) Modulation of HIV replication by RNA interference
JP2022508155A (ja) がんを治療する方法
Cascalho Advantages and disadvantages of cytidine deamination
JP2019533697A (ja) ５−ハロウラシル修飾マイクロｒｎａ及びがんの処置におけるその使用
Tsai et al. AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine
Thota et al. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia
KR20210139237A (ko) 변형된 마이크로rna 및 암 치료에 있어서의 이의 용도
Parker et al. 5-Aza-4′-thio-2′-deoxycytidine, a New Orally Bioavailable Nontoxic “Best-in-Class”: DNA Methyltransferase 1–Depleting Agent in Clinical Development
Kurup et al. Design, synthesis, and evaluation of a cross-linked oligonucleotide as the first nanomolar inhibitor of APOBEC3A
WO2019246430A1 (fr) Méthodes de traitement de troubles
Lavelle et al. Oral decitabine reactivates expression of the methylated γ‐globin gene in Papio anubis
AU2002322805A2 (en) Inhibitor of DNA methylation
TW202325313A (zh) Ｔｒｅｍ組合物及使用方法
Fan et al. Halogenated thymidine analogues restore the expression of silenced genes without demethylation
Clayette et al. Inhibition of human immunodeficiency virus infection by heparin derivatives
US20200222444A1 (en) Methods of inhibiting cell proliferation and mettl8 activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 11579660

Country of ref document: US